Acceleron Pharma Shares Gain Ground After FDA Approves Reblozyl
2019年11月9日 - 3:30AM
Dow Jones News
By Stephen Nakrosis
Shares of Acceleron Pharma Inc. (XLRN) are moving higher in
Friday's market, following the U.S. Food and Drug Administration's
announcement it had approved Reblozyl for the treatment of anemia
patients with beta thalassemia who require regular red blood cell
transfusions.
Celgene Corp. (CELG) and Acceleron are jointly developing
Reblozyl, the companies said.
At 12:55 p.m. EST, Acceleron shares had gained 6.01%, to trade
at $43.05.
Celgene shares were up 0.35%, to $109.38, following the
news.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
November 08, 2019 13:15 ET (18:15 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Celgene (NASDAQ:CELG)
過去 株価チャート
から 4 2024 まで 5 2024
Celgene (NASDAQ:CELG)
過去 株価チャート
から 5 2023 まで 5 2024
Real-Time news about Celgene Corporation (ナスダック市場): 0 recent articles
その他のCelgene Corporationニュース記事